3B Blackbio DX Ltd
₹ 2,001
3.21%
02 Jan
- close price
About
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
Key Points
- Market Cap ₹ 1,717 Cr.
- Current Price ₹ 2,001
- High / Low ₹ 2,350 / 695
- Stock P/E 39.8
- Book Value ₹ 291
- Dividend Yield 0.15 %
- ROCE 21.8 %
- ROE 16.1 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company is expected to give good quarter
- Company has delivered good profit growth of 140% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 37.9%
Cons
- Company has high debtors of 188 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20 | 21 | 18 | 16 | 13 | 16 | 12 | 14 | 14 | 16 | 59 | 71 | 83 | |
| 18 | 20 | 17 | 15 | 12 | 14 | 12 | 14 | 16 | 17 | 30 | 36 | 38 | |
| Operating Profit | 1 | 1 | 1 | 1 | 1 | 1 | 0 | -0 | -1 | -1 | 30 | 35 | 45 |
| OPM % | 7% | 6% | 7% | 7% | 8% | 7% | 4% | -2% | -8% | -8% | 50% | 50% | 54% |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 10 | 7 | 12 | 14 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 8 | 36 | 46 | 58 |
| Tax % | 27% | 14% | 21% | 23% | 14% | 9% | 2% | 0% | 18% | 5% | 26% | 26% | |
| 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 2 | 8 | 26 | 34 | 43 | |
| EPS in Rs | 0.89 | 0.59 | 0.34 | 0.30 | 0.36 | 0.81 | 0.67 | 0.81 | 2.29 | 10.67 | 35.19 | 39.86 | 50.27 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 83% | 61% | 74% | 86% | 392% | 98% | 8% | 8% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 42% |
| 3 Years: | 70% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 57% |
| 5 Years: | 140% |
| 3 Years: | 171% |
| TTM: | 47% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 71% |
| 5 Years: | 85% |
| 3 Years: | 61% |
| 1 Year: | 125% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 18% |
| 3 Years: | 20% |
| Last Year: | 16% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 7 | 7 | 7 | 9 | 9 | 9 |
| Reserves | 4 | 4 | 4 | 5 | 5 | 9 | 9 | 13 | 15 | 16 | 188 | 219 | 242 |
| 6 | 6 | 7 | 7 | 8 | 6 | 6 | 4 | 2 | 3 | 2 | 1 | 1 | |
| 7 | 7 | 7 | 6 | 5 | 5 | 5 | 4 | 4 | 5 | 16 | 21 | 18 | |
| Total Liabilities | 23 | 24 | 25 | 24 | 24 | 26 | 27 | 28 | 29 | 32 | 214 | 250 | 269 |
| 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 7 | 7 | 6 | |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 4 | 4 | 102 | 128 | 143 |
| 20 | 21 | 22 | 21 | 21 | 22 | 23 | 22 | 23 | 25 | 105 | 116 | 120 | |
| Total Assets | 23 | 24 | 25 | 24 | 24 | 26 | 27 | 28 | 29 | 32 | 214 | 250 | 269 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1 | 0 | 0 | 1 | 0 | -1 | 0 | 1 | 3 | 8 | 21 | 28 | |
| -0 | -0 | -0 | -0 | 0 | -0 | -0 | -2 | -0 | -2 | -8 | -20 | |
| -0 | 0 | -0 | -1 | -0 | 1 | -0 | 1 | -2 | -6 | -3 | -4 | |
| Net Cash Flow | -1 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 1 | 0 | 10 | 5 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 222 | 217 | 271 | 303 | 371 | 332 | 426 | 382 | 358 | 337 | 206 | 188 |
| Inventory Days | 136 | 106 | 128 | 121 | 190 | 108 | 176 | 116 | 88 | 81 | 154 | 144 |
| Days Payable | 204 | 175 | 204 | 190 | 237 | 115 | 156 | 108 | 95 | 108 | 63 | 65 |
| Cash Conversion Cycle | 155 | 148 | 196 | 234 | 323 | 326 | 447 | 390 | 351 | 311 | 297 | 267 |
| Working Capital Days | 219 | 222 | 282 | 331 | 428 | 410 | 549 | 494 | 447 | 431 | 255 | 225 |
| ROCE % | 9% | 7% | 6% | 5% | 6% | 6% | 4% | 4% | 9% | 34% | 32% | 22% |
Documents
Announcements
- Closure of Trading Window 24 Dec
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov 2024 - Newspaper Advertisement- Regulation 47 of SEBI (LODR) Regulations, 2015
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 13 Nov 2024
-
Announcement under Regulation 30 (LODR)-Investor Presentation
13 Nov 2024 - Investor presentation on financial performance and business outlook.
-
Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended On 30Th September 2024
13 Nov 2024 - Board approved unaudited financial results for Q2 FY2024.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Nov 2024TranscriptNotesPPT
-
Aug 2024TranscriptNotesPPT
-
May 2024TranscriptNotesPPT
-
Feb 2024TranscriptNotesPPT
-
Nov 2023TranscriptNotesPPT
-
Aug 2023TranscriptNotesPPT
-
May 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Sep 2022TranscriptNotesPPT
-
Aug 2022TranscriptNotesPPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021TranscriptNotesPPT
-
Sep 2021TranscriptNotesPPT
-
Jul 2021TranscriptNotesPPT
-
Jun 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Feb 2021TranscriptNotesPPT
-
Nov 2020TranscriptNotesPPT
-
Sep 2020TranscriptNotesPPT
-
Jul 2020TranscriptNotesPPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
May 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Nov 2018TranscriptNotesPPT
-
Aug 2018TranscriptNotesPPT
-
May 2018TranscriptNotesPPT
-
Feb 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Jul 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
Business Segments[1][2]
A) Diagnostics Business (81% of FY23 revenue)
3BDL is part of an Indo-Spanish JV and was formed by amalgamation with its parent company Kilpest India Limited. Company is an ISO 13485:2016 certified, GMP-compliant biotech R&D organization and is engaged in the design, development, manufacturing, and commercialization of Rapid tests, PCR-based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, NGS-based Molecular Diagnostic Kit